Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2018 | CLL11 trial shows improved OS rates in CLL with obinutuzumab

Barbara Eichhorst • 19 Jun 2018
EHA 2018
Chronic Lymphocytic Leukemia Leukemia Antibodies Chlorambucil Obinutuzumab Rituximab
CLL11

Barbara Eichhorst, MD, from Uniklink Koln, Koln, Germany discusses the results of the recent Phase III CLL11 trial (NCT01998880). The CLL11 trial compared different chemoimmunotherapy combinations of chlorambucil, rituximab and obinutuzumab in chronic lymphocytic leukaemia (CLL). Dr Eichhorst highlights the promising results, including a significant overall survival benefit with the anti-CD20 monoclonal antibody obinutuzumab. This video was recorded at the at the 23rd congress of the European Haematology Association (EHA) 2018, held in Stockholm, Sweden.

More from Barbara Eichhorst

1:05
Risk-factors for Richter’s transformation
Barbara Eichhorst • 10 Dec 2023
2:01
Updated follow-up results of the Phase III GAIA/CLL13 trial
Barbara Eichhorst • 10 Dec 2023
2:08
CLL-RT1 trial: primary endpoint analysis of tislelizumab plus zanubrutinib in patients with RT
Barbara Eichhorst • 10 Dec 2023
1:14
Current trials of interest in CLL
Barbara Eichhorst • 7 Oct 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals